{"id": "F7K-NJYAAAAJ", "citedby": 24236, "citedby5y": 13737, "hindex": 65, "hindex5y": 56, "i10index": 146, "i10index5y": 137, "coauthors": [], "name": "Anthony Letai", "affiliation": "Professor of Medicine, Dana-Farber Cancer Institute", "interests": ["Cancer", "mitochondria", "apoptosis"], "cites_per_year": {"2003": 70, "2004": 126, "2005": 222, "2006": 435, "2007": 612, "2008": 892, "2009": 819, "2010": 1099, "2011": 1199, "2012": 1488, "2013": 1646, "2014": 1679, "2015": 1790, "2016": 2115, "2017": 2449, "2018": 2701, "2019": 3143, "2020": 1468}, "publications": [{"bib": {"title": "An inhibitor of Bcl-2 family proteins induces regression of solid tumours", "year": "2005"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:u5HHmVD_uO8C", "citedby": "3298"}, {"bib": {"title": "The landscape of somatic copy-number alteration across human cancers", "year": "2010"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:d1gkVwhDpl0C", "citedby": "2798"}, {"bib": {"title": "Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics", "year": "2002"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:u-x6o8ySG0sC", "citedby": "1775"}, {"bib": {"title": "Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members", "year": "2006"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:9yKSN-GCB0IC", "citedby": "1177"}, {"bib": {"title": "Control of mitochondrial apoptosis by the Bcl-2 family", "year": "2009"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:UeHWp8X0CEIC", "citedby": "870"}, {"bib": {"title": "Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1", "year": "2003"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:2osOgNQ5qMEC", "citedby": "833"}, {"bib": {"title": "A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib", "year": "2005"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:qjMakFHDy7sC", "citedby": "726"}, {"bib": {"title": "Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737", "year": "2007"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:zYLM7Y9cAGgC", "citedby": "562"}, {"bib": {"title": "Diagnosing and exploiting cancer's addiction to blocks in apoptosis", "year": "2008"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:IjCSPb-OGe4C", "citedby": "558"}, {"bib": {"title": "BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents", "year": "2007"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:Tyk-4Ss8FVUC", "citedby": "475"}, {"bib": {"title": "Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy", "year": "2011"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:Y0pCki6q_DkC", "citedby": "449"}, {"bib": {"title": "Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:N5tVd3kTz84C", "citedby": "375"}, {"bib": {"title": "Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1", "year": "2010"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:W7OEmFMy1HYC", "citedby": "326"}, {"bib": {"title": "Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:YOwf2qJgpHMC", "citedby": "325"}, {"bib": {"title": "Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:sNmaIFBj_lkC", "citedby": "320"}, {"bib": {"title": "Precision medicine for cancer with next-generation functional diagnostics", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:V3AGJWp-ZtQC", "citedby": "304"}, {"bib": {"title": "Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:NJ774b8OgUMC", "citedby": "302"}, {"bib": {"title": "Mimicking the BH3 domain to kill cancer cells", "year": "2008"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:YsMSGLbcyi4C", "citedby": "267"}, {"bib": {"title": "Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors", "year": "2012"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:Se3iqnhoufwC", "citedby": "244"}, {"bib": {"title": "Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML", "year": "2012"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:UebtZRa9Y70C", "citedby": "239"}, {"bib": {"title": "Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label \u2026", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:q3CdL3IzO_QC", "citedby": "230"}, {"bib": {"title": "Targeting the B-cell lymphoma/leukemia 2 family in cancer", "year": "2012"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:_FxGoFyzp5QC", "citedby": "228"}, {"bib": {"title": "Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:r0BpntZqJG4C", "citedby": "212"}, {"bib": {"title": "BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia", "year": "2008"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:ufrVoPGSRksC", "citedby": "193"}, {"bib": {"title": "Antiapoptotic BCL-2 is required for maintenance of a model leukemia", "year": "2004"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:eQOLeE2rZwMC", "citedby": "188"}, {"bib": {"title": "Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:eq2jaN3J8jMC", "citedby": "180"}, {"bib": {"title": "Pharmacological manipulation of Bcl-2 family members to control cell death", "year": "2005"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:WF5omc3nYNoC", "citedby": "179"}, {"bib": {"title": "Mitochondria\u2014judges and executioners of cell death sentences", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:t6usbXjVLHcC", "citedby": "174"}, {"bib": {"title": "BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:qxL8FJ1GzNcC", "citedby": "169"}, {"bib": {"title": "The public repository of xenografts enables discovery and randomized phase II-like trials in mice", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:JoZmwDi-zQgC", "citedby": "151"}, {"bib": {"title": "Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:uWiczbcajpAC", "citedby": "145"}, {"bib": {"title": "The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:dTyEYWd-f8wC", "citedby": "145"}, {"bib": {"title": "KPT\u2010330 inhibitor of CRM 1 (XPO 1)\u2010mediated nuclear export has selective anti\u2010leukaemic activity in preclinical models of T\u2010cell acute lymphoblastic leukaemia and acute myeloid \u2026", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:0EnyYjriUFMC", "citedby": "141"}, {"bib": {"title": "Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion", "year": "2007"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:LkGwnXOMwfcC", "citedby": "141"}, {"bib": {"title": "Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes", "year": "2010"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:5nxA0vEk-isC", "citedby": "133"}, {"bib": {"title": "Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737", "year": "2008"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:roLk4NBRz8UC", "citedby": "133"}, {"bib": {"title": "BH3 profiling\u2013measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:M3ejUd6NZC8C", "citedby": "128"}, {"bib": {"title": "BH3 profiling in whole cells by fluorimeter or FACS", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:hFOr9nPyWt4C", "citedby": "118"}, {"bib": {"title": "Cancer, coagulation, and anticoagulation", "year": "1999"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:yqoGN6RLRZoC", "citedby": "117"}, {"bib": {"title": "Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:QYdC8u9Cj1oC", "citedby": "115"}, {"bib": {"title": "Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:R3hNpaxXUhUC", "citedby": "113"}, {"bib": {"title": "Why do BCL-2 inhibitors work and where should we use them in the clinic?", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:tuHXwOkdijsC", "citedby": "110"}, {"bib": {"title": "Regulation of Bcl-2 family proteins by posttranslational modifications", "year": "2008"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:8k81kl-MbHgC", "citedby": "108"}, {"bib": {"title": "Mitochondria: gatekeepers of response to chemotherapy", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:IWHjjKOFINEC", "citedby": "105"}, {"bib": {"title": "Aurora kinase A is a target of Wnt/\u03b2-catenin involved in multiple myeloma disease progression", "year": "2009"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:hqOjcs7Dif8C", "citedby": "105"}, {"bib": {"title": "p53 regulates a non-apoptotic death induced by ROS", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:4DMP91E08xMC", "citedby": "103"}, {"bib": {"title": "High mitochondrial priming sensitizes hESCs to DNA-damage-induced apoptosis", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:dhFuZR0502QC", "citedby": "103"}, {"bib": {"title": "Developmental regulation of mitochondrial apoptosis by c-Myc governs age-and tissue-specific sensitivity to cancer therapeutics", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:9Nmd_mFXekcC", "citedby": "101"}, {"bib": {"title": "Functional precision cancer medicine\u2014moving beyond pure genomics", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:tYavs44e6CUC", "citedby": "98"}, {"bib": {"title": "Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia", "year": "2012"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:4TOpqqG69KYC", "citedby": "97"}, {"bib": {"title": "Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:z_wVstp3MssC", "citedby": "86"}, {"bib": {"title": "Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells", "year": "2010"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:Zph67rFs4hoC", "citedby": "86"}, {"bib": {"title": "BH3\u2010only proteins are part of a regulatory network that control the sustained signalling of the unfolded protein response sensor IRE1\u03b1", "year": "2012"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:3fE2CSJIrl8C", "citedby": "84"}, {"bib": {"title": "Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release", "year": "2009"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:MXK_kJrjxJIC", "citedby": "84"}, {"bib": {"title": "Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:-f6ydRqryjwC", "citedby": "83"}, {"bib": {"title": "P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment", "year": "2012"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:Wp0gIr-vW9MC", "citedby": "79"}, {"bib": {"title": "BH3 peptides and method of use thereof", "year": "2004"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:FAceZFleit8C", "citedby": "79"}, {"bib": {"title": "BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:B3FOqHPlNUQC", "citedby": "78"}, {"bib": {"title": "MCL-1\u2013dependent leukemia cells are more sensitive to chemotherapy than BCL-2\u2013dependent counterparts", "year": "2009"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:kNdYIx-mwKoC", "citedby": "76"}, {"bib": {"title": "APCCdc20 suppresses apoptosis through targeting Bim for ubiquitination and destruction", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:mB3voiENLucC", "citedby": "74"}, {"bib": {"title": "Genomic evolution and chemoresistance in germ-cell tumours", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:-_dYPAW6P2MC", "citedby": "73"}, {"bib": {"title": "Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:j3f4tGmQtD8C", "citedby": "73"}, {"bib": {"title": "ABT-199: taking dead aim at BCL-2", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:9ZlFYXVOiuMC", "citedby": "72"}, {"bib": {"title": "A phase 1b study of venetoclax (ABT-199/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are\u2265 to 65 \u2026", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:HE397vMXCloC", "citedby": "67"}, {"bib": {"title": "Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:TQgYirikUcIC", "citedby": "67"}, {"bib": {"title": "MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:J-pR_7NvFogC", "citedby": "65"}, {"bib": {"title": "Bruton\u2019s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:uc_IGeMz5qoC", "citedby": "64"}, {"bib": {"title": "A phase 2 study of ABT-199 (GDC-0199) in patients with acute myelogenous leukemia (AML)", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:M3NEmzRMIkIC", "citedby": "61"}, {"bib": {"title": "Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH 3 mimetics\u2013recent successes, current challenges and future promise", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:PELIpwtuRlgC", "citedby": "59"}, {"bib": {"title": "Activity of the type II JAK2 inhibitor CHZ868 in B cell acute lymphoblastic leukemia", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:BqipwSGYUEgC", "citedby": "59"}, {"bib": {"title": "BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma", "year": "2006"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:KlAtU1dfN6UC", "citedby": "56"}, {"bib": {"title": "Targeting the miR-221\u2013222/PUMA/BAK/BAX pathway abrogates dexamethasone resistance in multiple myeloma", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:Fu2w8maKXqMC", "citedby": "54"}, {"bib": {"title": "Growth factor withdrawal and apoptosis: the middle game", "year": "2006"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:_kc_bZDykSQC", "citedby": "54"}, {"bib": {"title": "BCL-2: found bound and drugged!", "year": "2005"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:ULOm3_A8WrAC", "citedby": "52"}, {"bib": {"title": "BIM and other BCL-2 family proteins exhibit cross-species conservation of function between zebrafish and mammals", "year": "2008"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:QIV2ME_5wuYC", "citedby": "51"}, {"bib": {"title": "iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:olpn-zPbct0C", "citedby": "50"}, {"bib": {"title": "Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:isC4tDSrTZIC", "citedby": "50"}, {"bib": {"title": "Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016; 6: 1106\u20131117. doi \u2026"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:CaZNVDsoPx4C", "citedby": "50"}, {"bib": {"title": "Spatial proximity to fibroblasts impacts molecular features and therapeutic sensitivity of breast cancer cells influencing clinical outcomes", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:JQOojiI6XY0C", "citedby": "49"}, {"bib": {"title": "BH3 domains define selective inhibitory interactions with BHRF-1 and KSHV BCL-2", "year": "2008"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:aqlVkmm33-oC", "citedby": "49"}, {"bib": {"title": "Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:Dip1O2bNi0gC", "citedby": "47"}, {"bib": {"title": "Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:1sJd4Hv_s6UC", "citedby": "47"}, {"bib": {"title": "Bcl-xL controls a switch between cell death modes during mitotic arrest", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:4JMBOYKVnBMC", "citedby": "47"}, {"bib": {"title": "Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients\u2265 65 years ineligible for standard induction therapy.", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:1yQoGdGgb4wC", "citedby": "46"}, {"bib": {"title": "RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:NMxIlDl6LWMC", "citedby": "44"}, {"bib": {"title": "Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:RHpTSmoSYBkC", "citedby": "42"}, {"bib": {"title": "PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:anf4URPfarAC", "citedby": "40"}, {"bib": {"title": "The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance", "year": "2011"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:qUcmZB5y_30C", "citedby": "39"}, {"bib": {"title": "Iterative optimization yields Mcl-1\u2013targeting stapled peptides with selective cytotoxicity to Mcl-1\u2013dependent cancer cells", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:ruyezt5ZtCIC", "citedby": "38"}, {"bib": {"title": "Apoptosis and cancer", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:7T2F9Uy0os0C", "citedby": "38"}, {"bib": {"title": "PUMA strikes Bax", "year": "2009"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:mVmsd5A6BfQC", "citedby": "38"}, {"bib": {"title": "Inhibition of USP10 induces degradation of oncogenic FLT3", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:TIZ-Mc8IlK0C", "citedby": "37"}, {"bib": {"title": "Discovery and biological characterization of potent myeloid cell leukemia\u20101 inhibitors", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:VLnqNzywnoUC", "citedby": "37"}, {"bib": {"title": "Found in translation: how preclinical research is guiding the clinical development of the BCL2-selective inhibitor venetoclax", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:LI9QrySNdTsC", "citedby": "35"}, {"bib": {"title": "BCL2 suppresses PARP1 function and nonapoptotic cell death", "year": "2012"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:hC7cP41nSMkC", "citedby": "34"}, {"bib": {"title": "BCL-2 inhibition in AML: an unexpected bonus?", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:NXb4pA-qfm4C", "citedby": "33"}, {"bib": {"title": "BH3 domains as BCL-2 inhibitors: prototype cancer therapeutics", "year": "2003"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:ZeXyd9-uunAC", "citedby": "31"}, {"bib": {"title": "Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:_Qo2XoVZTnwC", "citedby": "30"}, {"bib": {"title": "Characterization and expression of SpHsp60 in hemocytes after challenge to bacterial, osmotic and thermal stress from the mud crab Scylla paramamosain", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:IUKN3-7HHlwC", "citedby": "29"}, {"bib": {"title": "Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:gsN89kCJA0AC", "citedby": "28"}, {"bib": {"title": "Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:AvfA0Oy_GE0C", "citedby": "28"}, {"bib": {"title": "Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:dQ2og3OwTAUC", "citedby": "28"}, {"bib": {"title": "Rapid optimization of Mcl-1 inhibitors using stapled peptide libraries including non-natural side chains", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:eMMeJKvmdy0C", "citedby": "28"}, {"bib": {"title": "Potent and specific peptide inhibitors of human pro-survival protein Bcl-xL", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:hMod-77fHWUC", "citedby": "27"}, {"bib": {"title": "Tight sequestration of BH3 proteins by BCL-xL at subcellular membranes contributes to apoptotic resistance", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:t7zJ5fGR-2UC", "citedby": "26"}, {"bib": {"title": "BH3-only proteins and their effects on cancer", "year": "2010"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:e5wmG9Sq2KIC", "citedby": "26"}, {"bib": {"title": "ER stress signaling promotes the survival of cancer \u201cpersister cells\u201d tolerant to EGFR tyrosine kinase inhibitors", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:foquWX3nUaYC", "citedby": "25"}, {"bib": {"title": "Updated safety and efficacy of venetoclax with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:oNZyr7d5Mn4C", "citedby": "25"}, {"bib": {"title": "Dynamic BH3 profiling-poking cancer cells with a stick", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:_B80troHkn4C", "citedby": "24"}, {"bib": {"title": "Methods of determining cellular chemosensitivity", "year": "2012"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:9pM33mqn1YgC", "citedby": "24"}, {"bib": {"title": "Rational design of therapeutics targeting the BCL-2 family: are some cancer cells primed for death but waiting for a final push?", "year": "2008"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:L8Ckcad2t8MC", "citedby": "24"}, {"bib": {"title": "To prime, or not to prime: that is the question", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:kzcrU_BdoSEC", "citedby": "23"}, {"bib": {"title": "Restoring cancer's death sentence", "year": "2006"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:7PzlFSSx8tAC", "citedby": "23"}, {"bib": {"title": "Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:lvd772isFD0C", "citedby": "20"}, {"bib": {"title": "MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:hCrLmN-GePgC", "citedby": "20"}, {"bib": {"title": "Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:4MWp96NkSFoC", "citedby": "20"}, {"bib": {"title": "Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:ODE9OILHJdcC", "citedby": "19"}, {"bib": {"title": "Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:O3NaXMp0MMsC", "citedby": "19"}, {"bib": {"title": "BH3 peptides and method of use thereof", "year": "2011"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:SeFeTyx0c_EC", "citedby": "19"}, {"bib": {"title": "Targeted inhibition of PI3K\u03b1/\u03b4 is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:umqufdRvDiIC", "citedby": "18"}, {"bib": {"title": "Ibrutinib therapy increases BCL-2 dependence and enhances sensitivity to venetoclax in CLL", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:XiVPGOgt02cC", "citedby": "18"}, {"bib": {"title": "S63845, an MCL-1 selective BH3 mimetic: another arrow in our quiver", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:uJ-U7cs_P_0C", "citedby": "17"}, {"bib": {"title": "Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:WA5NYHcadZ8C", "citedby": "17"}, {"bib": {"title": "Methods of bh3 profiling", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:ZuybSZzF8UAC", "citedby": "16"}, {"bib": {"title": "Venetoclax in combination with hypomethylating agents induces rapid, deep, and durable responses in patients with AML ineligible for intensive therapy", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:mlAyqtXpCwEC", "citedby": "15"}, {"bib": {"title": "SAFETY AND EFFICACY OF VENETOCLAX (VEN) IN COMBINATION WITH DECITABINE OR AZACITIDINE IN TREATMENT-NAIVE, ELDERLY PATIENTS (>= 65 YEARS) WITH ACUTE MYELOID LEUKEMIA (AML)", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:hMsQuOkrut0C", "citedby": "15"}, {"bib": {"title": "Cell death and cancer therapy: don't forget to kill the cancer cell!", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:1qzjygNMrQYC", "citedby": "15"}, {"bib": {"title": "Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:0izLItjtcgwC", "citedby": "14"}, {"bib": {"title": "Statins enhance efficacy of venetoclax in blood cancers", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:bz8QjSJIRt4C", "citedby": "14"}, {"bib": {"title": "Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:u9iWguZQMMsC", "citedby": "14"}, {"bib": {"title": "Antibodies specific to heterodimers of Bcl-2 family and uses thereof", "year": "2012"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:pqnbT2bcN3wC", "citedby": "14"}, {"bib": {"title": "Smallpox and smallpox vaccination.", "year": "2003"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:HDshCWvjkbEC", "citedby": "14"}, {"bib": {"title": "BCL-X L directly modulates RAS signalling to favour cancer cell stemness", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:kuK5TVdYjLIC", "citedby": "13"}, {"bib": {"title": "Pancreas-graft immunogenicity and pretreatment with anti-class II monoclonal antibodies", "year": "1989"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:_FM0Bhl9EiAC", "citedby": "12"}, {"bib": {"title": "DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:u-coK7KVo8oC", "citedby": "11"}, {"bib": {"title": "Dynamic BH3 profiling", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:wbdj-CoPYUoC", "citedby": "11"}, {"bib": {"title": "Durable response with venetoclax in combination with decitabine or azacitadine in elderly patients with acute myeloid leukemia (AML).", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:kh2fBNsKQNwC", "citedby": "11"}, {"bib": {"title": "Diminished apoptotic priming and ATM signalling confer a survival advantage onto aged haematopoietic stem cells in response to DNA damage", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:86PQX7AUzd4C", "citedby": "11"}, {"bib": {"title": "Methods of determining cellular chemosensitivity", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:35N4QoGY0k4C", "citedby": "11"}, {"bib": {"title": "MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:ZzlSgRqYykMC", "citedby": "10"}, {"bib": {"title": "Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:OTTXONDVkokC", "citedby": "10"}, {"bib": {"title": "PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:DUooU5lO8OsC", "citedby": "10"}, {"bib": {"title": "Overcoming mutational complexity in acute myeloid leukemia by inhibition of critical pathways", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:b1wdh0AR-JQC", "citedby": "10"}, {"bib": {"title": "Synergistic interactions with PI3K inhibition that induce apoptosis", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:ML0RJ9NH7IQC", "citedby": "10"}, {"bib": {"title": "Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:9vf0nzSNQJEC", "citedby": "10"}, {"bib": {"title": "Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:GnPB-g6toBAC", "citedby": "10"}, {"bib": {"title": "BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics", "year": "2020"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:8xutWZnSdmoC", "citedby": "9"}, {"bib": {"title": "Cristae remodeling causes acidification detected by integrated graphene sensor during mitochondrial outer membrane permeabilization", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:uLbwQdceFCQC", "citedby": "9"}, {"bib": {"title": "Methods of determining cellular chemosensitivity", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:UHK10RUVsp4C", "citedby": "9"}, {"bib": {"title": "Laying the foundations of programmed cell death", "year": "2006"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:iH-uZ7U-co4C", "citedby": "9"}, {"bib": {"title": "Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:4hFrxpcac9AC", "citedby": "8"}, {"bib": {"title": "BH3 peptides and methods of use thereof", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:WqliGbK-hY8C", "citedby": "8"}, {"bib": {"title": "BOK: Oddball of the BCL-2 Family", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:SdhP9T11ey4C", "citedby": "8"}, {"bib": {"title": "BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.", "year": "2008"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:XoXfffV-tXoC", "citedby": "8"}, {"bib": {"title": "The BCL-2 network: Mechanistic insights and therapeutic potential", "year": "2005"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:k_IJM867U9cC", "citedby": "8"}, {"bib": {"title": "Methods of determining cellular chemosensitivity", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:EYYDruWGBe4C", "citedby": "7"}, {"bib": {"title": "ABT-199: a new hope for selective BCL-2 inhibition", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:_xSYboBqXhAC", "citedby": "7"}, {"bib": {"title": "BH3 profiling demonstrates that restoration of apoptotic priming contributes to increased sensitivity to PI3K inhibition in stroma-exposed chronic lymphocytic leukemia cells", "year": "2011"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:JV2RwH3_ST0C", "citedby": "7"}, {"bib": {"title": "A new face of BCL-2 inhibition in CLL", "year": "2011"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:bEWYMUwI8FkC", "citedby": "7"}, {"bib": {"title": "Inhibition of MAPKinase pathway sensitizes thyroid cancer cells to ABT-737 induced apoptosis", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:vDijr-p_gm4C", "citedby": "6"}, {"bib": {"title": "BCL-2 inhibition: stemming the tide of myeloid malignancies", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:maZDTaKrznsC", "citedby": "6"}, {"bib": {"title": "Who put the \u201cA\u201d in Atg12: Autophagy or apoptosis?", "year": "2011"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:TFP_iSt0sucC", "citedby": "6"}, {"bib": {"title": "The MDM2 inhibitor NVP-CGM097 is highly active in a randomized preclinical trial of B-cell acute lymphoblastic leukemia patient derived xenografts", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:tkaPQYYpVKoC", "citedby": "5"}, {"bib": {"title": "BH3 profiling predicts clinical response in a phase II clinical trial of ABT-199 (GDC-0199) in acute myeloid leukemia", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:K3LRdlH-MEoC", "citedby": "5"}, {"bib": {"title": "Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:_OXeSy2IsFwC", "citedby": "4"}, {"bib": {"title": "Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:KbBQZpvPDL4C", "citedby": "4"}, {"bib": {"title": "31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:ipzZ9siozwsC", "citedby": "4"}, {"bib": {"title": "Who Put the\" A\" in Atg12: Autophagy or Apoptosis?", "year": "2011"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:blknAaTinKkC", "citedby": "4"}, {"bib": {"title": "Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:AHdEip9mkN0C", "citedby": "3"}, {"bib": {"title": "Reproductive outcomes of office hysteroscopic metroplasty in women with unexplained infertility with dysmorphic uterus", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:HeT0ZceujKMC", "citedby": "3"}, {"bib": {"title": "Anti-tumor (M1) macrophages secrete Cytokines that prime breast cancer cells for apoptosis", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:Z5m8FVwuT1cC", "citedby": "3"}, {"bib": {"title": "Upregulation of MAPK/MCL-1 maintaining mitochondrial oxidative phosphorylation confers acquired resistance to BCL-2 inhibitor venetoclax in AML", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:2KloaMYe4IUC", "citedby": "3"}, {"bib": {"title": "A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:6yz0xqPARnAC", "citedby": "2"}, {"bib": {"title": "Pooled genomic screens identify anti-apoptotic genes as targetable mediators of chemotherapy resistance in ovarian cancer", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:fbc8zXXH2BUC", "citedby": "2"}, {"bib": {"title": "Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms\u2019 tumor", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:9c2xU6iGI7YC", "citedby": "2"}, {"bib": {"title": "Genetic determinants of venetoclax resistance in lymphoid malignancies", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:WJVC3Jt7v1AC", "citedby": "2"}, {"bib": {"title": "High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:rmuvC79q63oC", "citedby": "2"}, {"bib": {"title": "Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:Mojj43d5GZwC", "citedby": "2"}, {"bib": {"title": "Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Is Highly BCL-2 Dependent and Sensitive to Venetoclax", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:j8SEvjWlNXcC", "citedby": "2"}, {"bib": {"title": "Acalabrutinib increases mitochondrial priming and enhances venetoclax sensitivity in CLL cells", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:evX43VCCuoAC", "citedby": "2"}, {"bib": {"title": "A PHASE I TRIAL OF A PHARMACODYNAMICALLY-CONCEIVED DECITABINE/THIOGUANINE COMBINATION IN PATIENTS WITH ADVANCED MYELOID MALIGNANCIES", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:PR6Y55bgFSsC", "citedby": "2"}, {"bib": {"title": "Apoptotic priming is regulated by a developmental program and predisposes children to therapy-induced toxicity", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:08ZZubdj9fEC", "citedby": "2"}, {"bib": {"title": "Type II JAK2 Inhibitor NVP-CHZ868 Is Active in Vivo Against JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs)", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:dfsIfKJdRG4C", "citedby": "2"}, {"bib": {"title": "Mitochondrial apoptotic priming is associated with clinical response to the Bcl-2 antagonist ABT-199 in chronic lymphocytic leukemia", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:M05iB0D1s5AC", "citedby": "2"}, {"bib": {"title": "Apoptosis, necrosis, and autophagy", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:VaXvl8Fpj5cC", "citedby": "2"}, {"bib": {"title": "BH3 profiling predicts on-target cell death due to selective inhibition of BCL-2 by ABT-199 in acute myelogenous leukemia", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:ns9cj8rnVeAC", "citedby": "2"}, {"bib": {"title": "Antibodies Specific to Heterodimers of Bcl-2 Family and Uses Thereof", "year": "2012"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:LO7wyVUgiFcC", "citedby": "2"}, {"bib": {"title": "Hiding from ABT-737 in lymph nodes", "year": "2009"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:YFjsv_pBGBYC", "citedby": "2"}, {"bib": {"title": "Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:4X0JR2_MtJMC", "citedby": "1"}, {"bib": {"title": "Discovery of a novel histone deacetylase 6 inhibitor that kills drug-resistant breast cancer", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:F9fV5C73w3QC", "citedby": "1"}, {"bib": {"title": "Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:4fGpz3EwCPoC", "citedby": "1"}, {"bib": {"title": "Dynamic BH3 Profiling Predicts for Clinical Response to Lenalidomide Plus Chemotherapy in Relapsed Acute Myeloid Leukemia", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:_5tno0g5mFcC", "citedby": "1"}, {"bib": {"title": "Bh3 peptides and methods of use thereof", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:a9-T7VOCCH8C", "citedby": "1"}, {"bib": {"title": "Compositions and methods for assessing toxicity using dynamic bh3 profiling", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:YohjEiUPhakC", "citedby": "1"}, {"bib": {"title": "Dynamic BH3 profiling reveals novel therapeutic strategies for the treatment of double-hit lymphoma", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:i2xiXl-TujoC", "citedby": "1"}, {"bib": {"title": "Dynamic BH3 profiling to assess the effects of novel agents on anti-apoptotic protein dependence of CLL cells", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:S16KYo8Pm5AC", "citedby": "1"}, {"bib": {"title": "A functional characterization of BCL2-family members identifies BH3 mimetics as potential therapeutics in T-cell lymphomas", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:fEOibwPWpKIC", "citedby": "1"}, {"bib": {"title": "PRC2 mutations induce resistance to conventional chemotherapy by inhibiting mitochondrial apoptosis in T-cell acute lymphoblastic leukemia", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:35r97b3x0nAC", "citedby": "1"}, {"bib": {"title": "FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML)", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:_Re3VWB3Y0AC", "citedby": "1"}, {"bib": {"title": "2.25 BH3 Profiling Demonstrates that CAL-101 Restores Apoptotic Priming in Stroma-Exposed Chronic Lymphocytic Leukemia Cells", "year": "2011"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:J_g5lzvAfSwC", "citedby": "1"}, {"bib": {"title": "Rituximab provides steroid-sparing therapy in new-onset chronic graft-versus-host disease: 0153", "year": "2011"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:tS2w5q8j5-wC", "citedby": "1"}, {"bib": {"title": "Nuclear BCL2 inhibits PARP1 enzymatic activity, DNA repair, and necrotic cell death", "year": "2010"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:HoB7MX3m0LUC", "citedby": "1"}, {"bib": {"title": "Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052.", "year": "2005"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:RGFaLdJalmkC", "citedby": "1"}, {"bib": {"title": "Dynamic bh3 profiling", "year": "2020"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:buQ7SEKw-1sC", "citedby": "0"}, {"bib": {"title": "Identifying cellular immune components that correlate with response to immunotherapy in breast cancer using murine models.", "year": "2020"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:wMgC3FpKEyYC", "citedby": "0"}, {"bib": {"title": "Abstract A81: Identifying cellular immune components that correlate with response to immunotherapy in breast cancer using murine models", "year": "2020"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:QD3KBmkZPeQC", "citedby": "0"}, {"bib": {"title": "Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re\u2010induction chemotherapy", "year": "2020"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:NyGDZy8z5eUC", "citedby": "0"}, {"bib": {"title": "Abstract P3-11-06: Pre-clinical assessment of combined ABT-263/Navitoclax and ABT-414 or ABBV-321 treatment for EGFR-expressing TNBC", "year": "2020"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:4xDN1ZYqzskC", "citedby": "0"}, {"bib": {"title": "Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 inhibition", "year": "2020"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:otzGkya1bYkC", "citedby": "0"}, {"bib": {"title": "A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with \u2026", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:Ak0FvsSvgGUC", "citedby": "0"}, {"bib": {"title": "Abstract AP14: POOLED GENOMIC SCREENS IDENTIFY ANTI-APOPTOTIC GENES AS MEDIATORS OF CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:sJsF-0ZLhtgC", "citedby": "0"}, {"bib": {"title": "Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:2tRrZ1ZAMYUC", "citedby": "0"}, {"bib": {"title": "MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:LgRImbQfgY4C", "citedby": "0"}, {"bib": {"title": "Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:Bg7qf7VwUHIC", "citedby": "0"}, {"bib": {"title": "Enhancer Rewiring Dependent Switch from BCL2 to MCL1 Dependency Predicts NOTCH1 Inhibition Response in T-ALL", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:BJbdYPG6LGMC", "citedby": "0"}, {"bib": {"title": "Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously \u2026", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:vDZJ-YLwNdEC", "citedby": "0"}, {"bib": {"title": "Lymphoma genetics", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:nVrZBo8bIpAC", "citedby": "0"}, {"bib": {"title": "COMPREHENSIVE CHARACTERIZATION OF THE INTRINSIC APOPTOTIC MACHINERY REVEALS THE MOLECULAR BLOCKS RESPONSIBLE FOR RESISTANCE TO CELL DEATH IN GLIOBLASTOMA", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:jL-93Qbq4QoC", "citedby": "0"}, {"bib": {"title": "POOLED GENOMIC SCREENS IDENTIFY ANTI-APOPTOTIC GENES AS MEDIATORS OF CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:PVgj2kMGcgYC", "citedby": "0"}, {"bib": {"title": "Individualized functional approach to tailoring acute myeloid leukemia therapy", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:Ehil0879vHcC", "citedby": "0"}, {"bib": {"title": "High-throughput dynamic BH3 profiling identifies active cancer therapies in solid tumors", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:P7Ujq4OLJYoC", "citedby": "0"}, {"bib": {"title": "Dynamic BH3 profiling identifies active combinations with conventional chemotherapy in non-small cell lung cancer", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:OP4eGU-M3BUC", "citedby": "0"}, {"bib": {"title": "Network modeling of drug resistance mechanisms and drug combinations in breast cancer", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:a3BOlSfXSfwC", "citedby": "0"}, {"bib": {"title": "Identifying cancer drug sensitivity using live cell imaging dynamic BH3 profiling of solid tumor core biopsies", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:LhH-TYMQEocC", "citedby": "0"}, {"bib": {"title": "MCL1 and DEDD promote urothelial carcinoma progression", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:fFSKOagxvKUC", "citedby": "0"}, {"bib": {"title": "Reprogrammation mitochondriale \u00e0 l\u2019origine de la r\u00e9sistance au v\u00e9n\u00e9toclax dans les h\u00e9mopathies lympho\u00efdes", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:F1b5ZUV5XREC", "citedby": "0"}, {"bib": {"title": "Targeted inhibition of PI3K a/d is synergistic with BCL-2 blockade in genetically de fi ned subtypes of DLBCL", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:GFxP56DSvIMC", "citedby": "0"}, {"bib": {"title": "Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma", "year": "2019"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:XvxMoLDsR5gC", "citedby": "0"}, {"bib": {"title": "Targeted inhibition of PI3K\u03b1/\u03b4 is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:uDGL6kOW6j0C", "citedby": "0"}, {"bib": {"title": "PRC2 Inactivation Induces Resistance to Chemotherapy-Induced Apoptosis By Upregulating the TRAP1 Mitochondrial Chaperone in T-ALL", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:IRz6iEL74y4C", "citedby": "0"}, {"bib": {"title": "Apoptotic Blocks in Primary Non-Hodgkin B-Cell Lymphomas Identified By BH3 Profiling", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:2VqYfGB8ITEC", "citedby": "0"}, {"bib": {"title": "Targeting Cell Death Pathways with Precision Using Functional Assays", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:6ZxmRoH8BuwC", "citedby": "0"}, {"bib": {"title": "Class IIa HDAC inhibition promotes an antitumor macrophage phenotype that induces breast tumor regression and inhibits metastasis", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:OcBU2YAGkTUC", "citedby": "0"}, {"bib": {"title": "Durable Response with Venetoclax in Combination with Decitabine or Azacitidine in Elderly Patients with Acute Myeloid Leukemia", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:HtEfBTGE9r8C", "citedby": "0"}, {"bib": {"title": "Abstract B35: Class IIa HDAC inhibition promotes an antitumor macrophage phenotype that induces breast tumor regression and inhibits metastasis", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:epqYDVWIO7EC", "citedby": "0"}, {"bib": {"title": "Targeting B-Cell Lymphoma 2: A Lethal Shortcut in Del (17p) Chronic Lymphocytic Leukemia", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:Ri6SYOTghG4C", "citedby": "0"}, {"bib": {"title": "Safety and Efficacy of Venetoclax (VEN) in Combination With Decitabine or Azacitidine in Treatment-Naive, Elderly Patients (>= 65 Years) With Acute Myeloid Leukemia (AML)", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:_axFR9aDTf0C", "citedby": "0"}, {"bib": {"title": "Abstract P3-05-05: Class IIa HDAC inhibition promotes an anti-tumor macrophage phenotype that induces breast tumor regression and inhibits metastasis", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:PVjk1bu6vJQC", "citedby": "0"}, {"bib": {"title": "Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance", "year": "2018"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:yMeIxYmEMEAC", "citedby": "0"}, {"bib": {"title": "Characterization and treatment of a novel adoptive transfer model of Sf3b1mut/Atmdel chronic lymphocytic leukemia", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:HbR8gkJAVGIC", "citedby": "0"}, {"bib": {"title": "Abstract IA19: Directing blood cancer therapy with mitochondrial BH3 profiling", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:xtoqd-5pKcoC", "citedby": "0"}, {"bib": {"title": "Abstract PR14: Polycomb repressive complex 2 inactivation induces primary chemotherapy resistance in T-ALL by upregulating the TRAP1 mitochondrial chaperone", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:PoWvk5oyLR8C", "citedby": "0"}, {"bib": {"title": "Understanding Apoptotic Blocks in Double Hit and Other Non-Hodgkin Lymphomas By BH3 Profiling", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:e_rmSamDkqQC", "citedby": "0"}, {"bib": {"title": "A Functional Approach to Precision Medicine Identifies Targeted Therapies for Acute Myeloid Leukemia", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:-FonjvnnhkoC", "citedby": "0"}, {"bib": {"title": "Splicing Modulation Perturbs Key Survival Pathways and Sensitizes Chronic Lymphocytic Leukemia to Venetoclax Treatment", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:WZBGuue-350C", "citedby": "0"}, {"bib": {"title": "Characterization and treatment of a novel adoptive transfer model of Sf3b1 (mut)/Atm (del) chronic lymphocytic leukemia.", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:5qfkUJPXOUwC", "citedby": "0"}, {"bib": {"title": "Directing blood cancer therapy with mitochondrial BH3 profiling.", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:ClCfbGk0d_YC", "citedby": "0"}, {"bib": {"title": "Polycomb repressive complex 2 inactivation induces primary chemotherapy resistance in T-ALL by upregulating the TRAP1 mitochondrial chaperone.", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:FPJr55Dyh1AC", "citedby": "0"}, {"bib": {"title": "T-cell lymphomas have targetable dependences on BCL-2, BCL-xL, and MCL-1.", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:0N-VGjzr574C", "citedby": "0"}, {"bib": {"title": "Probing mitochondria to guide personalized therapy for acute myeloid leukemia.", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:edDO8Oi4QzsC", "citedby": "0"}, {"bib": {"title": "Webinar| Deciphering cancer: Investigating cell death mechanisms", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:MLfJN-KU85MC", "citedby": "0"}, {"bib": {"title": "Functional Mitochondrial Apoptosis Signaling Indicates Anti-Leukemia Activity of the BCL-2-Seletive Inhibitor ABT-199 in BCP-ALL", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:lmc2jWPfTJgC", "citedby": "0"}, {"bib": {"title": "Upregulation of MCL-1 through MAPK Activation Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:KUbvn5osdkgC", "citedby": "0"}, {"bib": {"title": "BH3 Mimetics May Have Utility in T Cell Non-Hodgkin Lymphomas", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:g3aElNc5_aQC", "citedby": "0"}, {"bib": {"title": "Prohibitin is a prognostic marker of treatment failure and therapeutic target to block chemotherapy resistance in Wilms tumor", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:L7CI7m0gUJcC", "citedby": "0"}, {"bib": {"title": "A high-throughput screen identified cancer selective small molecules that kill independent of mitochondrial apoptosis", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:vbGhcppDl1QC", "citedby": "0"}, {"bib": {"title": "PREDICTING ANTI-LEUKEMIA ACTIVITY OF THE BCL-2-SELECTIVE INHIBITOR ABT-199 IN BCP-ALL BY FUNCTIONAL ASSESSMENT OF APOPTOSIS SIGNALING", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:ILKRHgRFtOwC", "citedby": "0"}, {"bib": {"title": "Potent and Specific Peptide Inhibitors of Human Pro-Survival Protein Bcl-xL", "year": "2017"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:nZcligLrVowC", "citedby": "0"}, {"bib": {"title": "Statins Potentiate the Cytotoxic Effect of ABT-199 in Diffuse Large B Cell Lymphoma", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:tzM49s52ZIMC", "citedby": "0"}, {"bib": {"title": "Aberrant Phosphorylation of MEF2C Is Dispensable for Hematopoiesis, and Induces Chemotherapy Resistance and Susceptibility to MARK Kinase Inhibition Therapy in Acute Myeloid \u2026", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:ZfRJV9d4-WMC", "citedby": "0"}, {"bib": {"title": "Thioguanine Combined with Decitabine Can Overcome Resistance to Hypomethylating Agents: Final Results of a Phase I Trial of a Pharmacodynamically-Conceived Thioguanine \u2026", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:tKAzc9rXhukC", "citedby": "0"}, {"bib": {"title": "Abstract B038: Class IIa HDAC inhibition promotes an antitumor macrophage phenotype that induces breast tumor regression and inhibits metastasis", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:_Ybze24A_UAC", "citedby": "0"}, {"bib": {"title": "HYDROCARBON STAPLED PEPTIDE ANTAGONISTS AS NOVEL AGENTS FOR TARGETING MCL-1", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:BwyfMAYsbu0C", "citedby": "0"}, {"bib": {"title": "A Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:hkOj_22Ku90C", "citedby": "0"}, {"bib": {"title": "Targeting hyaluronan sensitizes breast cancer-associated fibroblasts to lapatinib and overcomes stromal resistance", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:3htObqc8RwsC", "citedby": "0"}, {"bib": {"title": "Abstract B24: Targeting hyaluronan sensitizes breast cancer-associated fibroblasts to lapatinib and overcomes stromal resistance", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:W5xh706n7nkC", "citedby": "0"}, {"bib": {"title": "Mitochondrial perturbations as a novel approach to personalized medicine", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:VL0QpB8kHFEC", "citedby": "0"}, {"bib": {"title": "Abstract SY43-01: Precision cancer medicine using BH3 profiling", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:ye4kPcJQO24C", "citedby": "0"}, {"bib": {"title": "Rational combination of targeted agents and BH3 mimetics to improve cancer treatment", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:LjlpjdlvIbIC", "citedby": "0"}, {"bib": {"title": "PERSPECTIVES \u6b21\u4e16\u4ee3\u6a5f\u80fd\u7684\u8a3a\u65ad\u6cd5\u306b\u3088\u308b\u304c\u3093\u306e\u7cbe\u5bc6\u533b\u7642 (precision medicine)", "year": "2016"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:0KyAp5RtaNEC", "citedby": "0"}, {"bib": {"title": "Abstract C6: Antiapoptotic defense evolution in cancer: novel therapeutic strategies to restore cell death using dynamic BH3 profiling", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:Y5dfb0dijaUC", "citedby": "0"}, {"bib": {"title": "Abstract A71: Modulation of macrophages in breast tumors towards an anti-tumor phenotype", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:mvPsJ3kp5DgC", "citedby": "0"}, {"bib": {"title": "Ibrutinib therapy increases BCL2 dependence and enhances sensitivity to venetoclax in CLL patients", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:AXPGKjj_ei8C", "citedby": "0"}, {"bib": {"title": "Abstract IA29: Using mitochondria to guide leukemia therapy.", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:eJXPG6dFmWUC", "citedby": "0"}, {"bib": {"title": "Abstract B10: Studying BCL-2 dependence using BH3 profiling in a phase 2 clinical trial of ABT-199 in acute myeloid leukemia.", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:vV6vV6tmYwMC", "citedby": "0"}, {"bib": {"title": "Novel compound elicits anti-tumor macrophages associated with tumor regression in breast cancer", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:P5F9QuxV20EC", "citedby": "0"}, {"bib": {"title": "Abstract SY20-01: Conventional chemotherapy cures people by exploiting apoptotic priming", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:D03iK_w7-QYC", "citedby": "0"}, {"bib": {"title": "Broad therapy resistance is induced by suppression of apoptotic priming by lineage programs and oncogenic activation", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:70eg2SAEIzsC", "citedby": "0"}, {"bib": {"title": "Polarizing tumor associated macrophages (TAMs) towards an anti-tumor phenotype with a novel compound reveals a new subset of TAMs within breast tumors which facilitate tumor \u2026", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:lSLTfruPkqcC", "citedby": "0"}, {"bib": {"title": "COMPLEMENTARY DYNAMIC BH3 PROFILES PREDICT INDUCTION OF APOPTOSIS BY THE MULTI-KINASE INHIBITOR TG02 IN COMBINATION WITH THE BH3 MIMETIC ABT-199 IN AML CELLS", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:kRWSkSYxWN8C", "citedby": "0"}, {"bib": {"title": "A phase I trial of a pharmacodynamically-conceived decitabine/thioguanine combination in patients with advanced myeloid malignancies.", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:EkHepimYqZsC", "citedby": "0"}, {"bib": {"title": "Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4\u00e2 \u00ba CD8\u00e2 \u00ba thymocytes", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:p__nRnzSRKYC", "citedby": "0"}, {"bib": {"title": "Abstract A17: Modulation of tumor-associated macrophages towards an antitumor phenotype", "year": "2015"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:CHSYGLWDkRkC", "citedby": "0"}, {"bib": {"title": "BH3 Profiling Identifies Bcl-2 Dependency in Multiple Myeloma and Predicts Sensitivity to BH3 Mimetics", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:NhqRSupF_l8C", "citedby": "0"}, {"bib": {"title": "Low-Dose IL-2 Reduces Mitochondrial Priming and Increases Bcl2 Expression in CD4 Memory Regulatory T Cells", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:EUQCXRtRnyEC", "citedby": "0"}, {"bib": {"title": "A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:2P1L_qKh6hAC", "citedby": "0"}, {"bib": {"title": "Abstract B26: Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:DJbcl8HfkQkC", "citedby": "0"}, {"bib": {"title": "Hitting the target: Dynamic BH3 profiling, a novel functional assay to predict chemotherapy response", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:BrmTIyaxlBUC", "citedby": "0"}, {"bib": {"title": "Targeting BCL-2 in hypodiploid acute lymphoblastic leukemia", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:SP6oXDckpogC", "citedby": "0"}, {"bib": {"title": "The level of mitochondrial apoptotic priming determines cell fate upon p53 restoration", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:a0OBvERweLwC", "citedby": "0"}, {"bib": {"title": "Targeting the Bcl-2 Pathway", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:Ug5p-4gJ2f0C", "citedby": "0"}, {"bib": {"title": "51INTARGETING THE BCL-2 PATHWAY.", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:nb7KW1ujOQ8C", "citedby": "0"}, {"bib": {"title": "Antibodies Specific to Heterodimers of Bcl-2 Family and Uses Thereof", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:GtLg2Ama23sC", "citedby": "0"}, {"bib": {"title": "715: BCL-2 dependence in T-cell leukemia is defined by the maturation stage of the clone of origin", "year": "2014"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:tOudhMTPpwUC", "citedby": "0"}, {"bib": {"title": "Therapeutic Targeting of the Bcl2 Family", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:artPoR2Yc-kC", "citedby": "0"}, {"bib": {"title": "HSP90 Inhibition Has Potent Activity Against T-Cell Acute Lymphoblastic Leukemia (T-ALL) Through Degradation Of TYK2 Kinase", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:fQNAKQ3IYiAC", "citedby": "0"}, {"bib": {"title": "Low-Dose IL-2 Induces Bcl2 Expression and Resistance To Apoptosis In CD4 Regulatory T Cells", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:uWQEDVKXjbEC", "citedby": "0"}, {"bib": {"title": "Alterations In Mitochondrial Priming May Be a Mechanism For Acquired Resistance To Therapy In Diffuse Large B-Cell Lymphoma", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:g5m5HwL7SMYC", "citedby": "0"}, {"bib": {"title": "Abstract CN04-01: Poking cancer cells with BH3 profiling to personalize cancer therapy.", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:p2g8aNsByqUC", "citedby": "0"}, {"bib": {"title": "Abstract C17: Genome-wide siRNA screen identifies diverse signaling pathways converging at mitochondria to regulate cell death.", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:bFI3QPDXJZMC", "citedby": "0"}, {"bib": {"title": "c-Myc and Ras differentially regulate mitochondrial apoptotic priming and chemosensitivity.", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:VOx2b1Wkg3QC", "citedby": "0"}, {"bib": {"title": "BAX and BAK are preferentially activated by BIM and BID, respectively, affecting clinical chemotherapy response.", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:8AbLer7MMksC", "citedby": "0"}, {"bib": {"title": "Personalizing cancer therapy using dynamic BH3 profiling.", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:4OULZ7Gr8RgC", "citedby": "0"}, {"bib": {"title": "Small molecule inhibitors of membrane-bound MCL-1 and BCL-2.", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:rO6llkc54NcC", "citedby": "0"}, {"bib": {"title": "Rituximab Provides Steroid-Sparing Therapy in New-Onset Chronic Graft-Versus-Host Disease", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:HIFyuExEbWQC", "citedby": "0"}, {"bib": {"title": "Spatial proximity to fibroblasts impacts molecular features and therapeutic sensitivity of", "year": "2013"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:k8Z6L05lTy4C", "citedby": "0"}, {"bib": {"title": "Differential Effects of TCR Stimulation and IL-2 On Apoptotic Pathways in CD4 Regulatory T Cells Compared to Conventional CD4 T Cells and CD8 T Cells", "year": "2012"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:5awf1xo2G04C", "citedby": "0"}, {"bib": {"title": "427 The mitochondrial basis of resistance to BCL-2 antagonists and conventional chemotherapy", "year": "2012"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:ZHo1McVdvXMC", "citedby": "0"}, {"bib": {"title": "A subset of small cell lung cancer (SCLC) cell lines is Mcl-1-dependent and responds to cyclin-dependent kinase (cdk) 9 inhibition in vitro and in vivo", "year": "2012"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:pyW8ca7W8N0C", "citedby": "0"}, {"bib": {"title": "Manipulating the Noxa/Bim axis undermines the multicellular resistance of 3D tumor spheroids", "year": "2012"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:yD5IFk8b50cC", "citedby": "0"}, {"bib": {"title": "Mitochondrial Apoptotic Priming Measured by BH3 Profiling Regulates Clinical Response to Chemotherapy in Myeloma and Acute Lymphoblastic Leukemia and Explains Therapeutic Index", "year": "2011"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:l7t_Zn2s7bgC", "citedby": "0"}, {"bib": {"title": "Using BH3 Profiling As a Predictive Indicator for Myeloma Patient Response to Bortezomib", "year": "2011"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:UxriW0iASnsC", "citedby": "0"}, {"bib": {"title": "Measuring Mitochondrial Apoptotic Priming by BH3 Profiling Predicts Induction Outcome for Acute Myeloid Leukemia Patients", "year": "2011"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:dshw04ExmUIC", "citedby": "0"}, {"bib": {"title": "Targeting Bcl-2 in CLL: cui bono?", "year": "2011"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:NaGl4SEjCO4C", "citedby": "0"}, {"bib": {"title": "5 The Control of Mitochondrial Apoptosis", "year": "2011"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:3s1wT3WcHBgC", "citedby": "0"}, {"bib": {"title": "Abstract LB-22: A subset of small cell lung cancer (SCLC) cell lines is Mcl-1-dependent and responds to cyclin-dependent kinase (cdk) 9 inhibition in vitro and in vivo", "year": "2011"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:ldfaerwXgEUC", "citedby": "0"}, {"bib": {"title": "BH3 Profiling\u2013A Predictive Biomarker for Apoptotic Response to Chemotherapy", "year": "2011"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:q3oQSFYPqjQC", "citedby": "0"}, {"bib": {"title": "BH3 Profiling Demonstrates Decreased Mitochondrial Priming for Apoptosis In Primary CLL Cells Exposed to Stroma", "year": "2010"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:4fKUyHm3Qg0C", "citedby": "0"}, {"bib": {"title": "Fauxcoll gradient", "year": "2010"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:RYcK_YlVTxYC", "citedby": "0"}, {"bib": {"title": "Lymphoma g enetics", "year": "2010"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:fPk4N6BV_jEC", "citedby": "0"}, {"bib": {"title": "Testing the BCL-2 Family to Direct Therapy and Predict Response.", "year": "2009"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:OU6Ihb5iCvQC", "citedby": "0"}, {"bib": {"title": "Abstract# SY34-1: Targeting BCL-2 family control of apoptosis in cancer", "year": "2009"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:abG-DnoFyZgC", "citedby": "0"}, {"bib": {"title": "Harnessing apoptosis to kill breast cancer cells.", "year": "2009"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:5Ul4iDaHHb8C", "citedby": "0"}, {"bib": {"title": "Apoptosis Dysregulation in CLL", "year": "2008"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:zA6iFVUQeVQC", "citedby": "0"}, {"bib": {"title": "BH3 profiling can determine dependence on antiapoptotic Bcl-2 family members and can predict response to chemotherapeutic agents.", "year": "2008"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:XiSMed-E-HIC", "citedby": "0"}, {"bib": {"title": "Restoring apoptosis to lymphoma by targeting BCL-2", "year": "2008"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:u_35RYKgDlwC", "citedby": "0"}, {"bib": {"title": "Detecting Apoptotic Blocks and Sensitvity to ABT-737 and Conventional Chemotherapy Via BH3 Profiling.", "year": "2007"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:Tiz5es2fbqcC", "citedby": "0"}, {"bib": {"title": "BCL-2 antagonist ABT-737 induces apoptosis in CLL cells by disrupting a BIM: BCL: 2 complex", "year": "2006"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:geHnlv5EZngC", "citedby": "0"}, {"bib": {"title": "The Molecular Basis for BCL-2 Oncogene Addiction in CLL.", "year": "2005"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:WbkHhVStYXYC", "citedby": "0"}, {"bib": {"title": "Lymphoid Neoplasms", "year": "2005"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:738O_yMBCRsC", "citedby": "0"}, {"bib": {"title": "Novel compounds", "year": "2003"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:5icHVeHT4IsC", "citedby": "0"}, {"bib": {"title": "Full wwPDB NMR Structure Validation Report i\u25cb"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:0CzhzZyukY4C", "citedby": "0"}, {"bib": {"title": "Decreased mitochondrial apoptotic priming underlies stroma-mediated"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:D_sINldO8mEC", "citedby": "0"}, {"bib": {"title": "Cell\u2014October 12, 151_2"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:vRqMK49ujn8C", "citedby": "0"}, {"bib": {"title": "Parkin selectively regulates BH3 peptide-induced mitochondrial cytochrome c release"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:xtRiw3GOFMkC", "citedby": "0"}, {"bib": {"title": "MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, PC ONE FINANCIAL CENTER BOSTON MA"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:b0M2c_1WBrUC", "citedby": "0"}, {"bib": {"title": "Supplemental data Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:f2IySw72cVMC", "citedby": "0"}, {"bib": {"title": "The contribution of autophagy and the proteasome to the anti-apoptotic effects of parkin"}, "source": "citations", "id_citations": "F7K-NJYAAAAJ:cFHS6HbyZ2cC", "citedby": "0"}]}